

**Curriculum Vitae for: GIL LICHTSHEIN, M.D.**

**Gil Lichtshein, M.D., P.A.**

**7100 West Camino Real, Suite 404**

**Boca Raton, FL 33433**

**Tel: 561-300-4052**

**Email: info@docgil.com**

**Web: www.docgil.com and www.tmsdelraybeach.com**

**EDUCATION**

Child and Adolescent Psychiatry Fellowship University of Maryland at Baltimore  
Baltimore, MD 21201

July 1997-June 1999

(Including Child Psychiatry Chief Fellow January 1999-June 1999)

PGY-2, PGY-3, Psychiatry University of Maryland at Baltimore

Baltimore, MD 21201

July 1995-June 1997

PGY-1, Psychiatry Medical College of Virginia Hospital

Virginia Commonwealth University

Richmond, VA 23298

June 1994-June 1995

(Including 3 months Pediatrics, 2 months Neurology, 1 month Emergency Medicine)

M.D., University of Illinois at Chicago College of Medicine

Chicago, IL 60612

August 1990-May 1994

B.A. Yeshiva University

New York, NY 10033

August 1988-May 1990

Major: History

Loyola University of Chicago

Chicago, IL 60626

August 1986-May 1988

**HONORS**

Undergraduate Dean's List: 1986-1990

Summa Cum Laude, Yeshiva University, May 1990

Child Psychiatry Chief Fellow, University of Maryland at Baltimore, January-June 1999

## **CERTIFICATIONS**

American Board of Psychiatry and Neurology, Inc., Psychiatry, Certificate # 48062  
American Board of Psychiatry and Neurology, Inc., Child and Adolescent Psychiatry  
Certificate # 5061

## **ACADEMIC APPOINTMENTS**

Courtesy Assistant Professor of Psychiatry, University of Florida School of Medicine  
Department of Psychiatry, Gainesville, FL, 12/12/08-present

Voluntary Assistant Professor of Psychiatry and Behavioral Sciences, University of  
Miami Miller School of Medicine Department of Psychiatry, Miami, FL, 11/13/08-  
present

Clinical Affiliate Associate Professor of Child and Adolescent Psychiatry, Department  
of Clinical Neurosciences, Charles E. Schmidt College of Medicine, Florida Atlantic  
University, Boca Raton, FL, 1/21/05-Present

Assistant Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of  
Medicine, Bronx, NY, 2000-2004

## **LICENSURE**

Licensed to practice medicine in the state of Florida, #ME87712

## **PUBLICATIONS**

Fernandez A. **Lichtsheim G.** (1995) THE Charles Bonnet Syndrome. Correspondence.  
*British Journal of Psychiatry.* 167, 115.

Fernandez A. **Lichtsheim G.** Viewer W. V.R. and Winfrey C. J. (1996) Charles Bonnet  
Syndrome with Peripheral and Central Findings-a Case Report.  
*International Journal of Geriatric Psychiatry,* 11-773-778.

Fernandez A. **Lichtsheim G.** and Viewer W.V.R, (1997) The Charles Bonnet Syndrome:  
A review. *The Journal of Nervous and Mental Disease,* 185: 195-200.

## **CLINICAL RESEARCH**

- 2011- 2015                      Sub-Investigator, Health Sciences America, Inc, Boca Raton, FL
- Sub-Investigator, Merck. 26 Week Open Label Flexible Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I D/O, 2011
- Sub-Investigator, Merck. Efficacy and Safety of 3 Week Fixed Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episode Associated with Bipolar I D/O, 2011
- 2005– Present                      Clinical Investigator, Psychopharmacology Research, Florida Atlantic University, Dept of Integrated Medical Science, Charles E. Schmidt College of Medicine, Boca Raton, FL.
- Clinical Investigator, Eli Lilly and Company. A phase 3 randomized, double-blind, placebo controlled study of the safety and effectiveness of immune globulin intravenous, 10% solution for the treatment of mild to moderate Alzheimer’s Disease, 2013.
- Clinical Investigator, Eli Lilly and Company. Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab versus Placebo, 2013.
- Clinical Investigator, Eisai Medical Research Inc. A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease, 2013
- Clinical Investigator, Genetech/Roche. A Multicenter, Open-Label, Long-term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients with Mild to Moderate Alzheimer’s Disease, 2013
- Clinical Investigator, Baxter. A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous(Human), 10% Solution(IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease, 2012
- Clinical Investigator, Takeda. A Randomized Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 v Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive

Disorder Experiencing Selective Serotonin Reuptake Inhibition-Induced Sexual Dysfunction, 2011

Clinical Investigator, Genentech. A Randomized Double Blind, Placebo Controlled, Parallel Group, Multicenter, Phase II Study To Evaluate The Efficacy And Safety Of MABT5102A In Patients With Mild To Moderate Alzheimer's Disease, 2011

Clinical Investigator, Eli Lilly and Company. Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid Beta Antibody in Patients with Alzheimer's Disease, 2011

Clinical Investigator, Novartis. A 24 week Open-Label Extension to a 24 Week Prospective, Randomized, Parallel-Group, Double-Blind, Multi Center Study Comparing the Effects of Rivastigmine Patch 15cm<sup>2</sup> Vs. Rivastigmine Patch 5 cm<sup>2</sup> on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type, 2010

Clinical Investigator, Forest Research Institute. A Double-blind, Placebo-Controlled Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder, 2009

Clinical Investigator, Novartis. A 24 week Prospective, Randomized, Parallel-Group, Double-Blind, Multi Center Study Comparing the Effects of Rivastigmine Patch 15cm<sup>2</sup> Vs. Rivastigmine Patch 5 cm<sup>2</sup> on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type, 2009

Clinical Investigator. Pfizer. A Phase 3, Randomized, Double-Blind, Parallel Group, 10-week Placebo Controlled Fixed Dose Study of PD 0332334 for the Treatment of Generalized Anxiety Disorder, 2008

Clinical Investigator. Pfizer. A 52 Week Open-Label Safety Study of PD 0332334 in Subjects with Generalized Anxiety Disorder, 2008

Sub Investigator for Schwarz-Pharma trial, A Multicenter Randomized, Open Label Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment with Nirivam and an SSRI or SNRI to Treatment with an SSRI or SNRI Alone in Subjects with Generalized Anxiety Disorder or Panic Disorder, 2007

## **PRESENTATIONS**

**Lichtshein G.** and Fernandez A. “Organic hallucinosis in the visually impaired”, Presented at the Department of Ophthalmology Grand Rounds, MCV Hospital, Richmond, VA February 1995.

**Lichtshein G,** Fernandez A. and Dixon L.B. A central hypothesis for the Charles Bonnet Syndrome presented at the American Psychiatric Association 149<sup>th</sup> Annual Meeting, New York, NY, Young Investigator’s Poster Session, May 6, 1996.

“Child and Adolescent Depression”, Mt. St. Mary’s College, Newburgh, NY May 23, 2001

“Update on medications and ADHD and co morbid disorders; including the many new extended release formulations”, CHADD of Putnam and Vicinity, Katonah, NY December 3, 2002

“Management of Childhood OCD”, La Viella Maison, Boca Raton, FL, October 29, 2003

“Medication 101”, The Coalition Group, Boca Raton, FL November 20, 2003

“Medication 101”, The Coalition Group, Boca Raton, FL February 13, 2003

“ADHD: Update on Treatment” CHADD of North Broward, Coral Springs, FL February 24, 2004

“Pharmacological Treatment of Asperger’s”, Center for Autism and Related Disabilities, Boca Raton, FL September 21, 2004

Pharmacological Treatment of Asperger’s”, Center for Autism and Related Disabilities, Jupiter, FL October 26, 2004

“Basic Principals of Psychopharmacology”, Dan Marino Center, Weston, FL December 12, 2004

OCD v Healthy Ritual Observance, South Florida Orthodox Mental Health Retreat. Sunny Isles Beach, FL March 11, 2005

Intensive Skills Training: What Are We Dealing With Here? Psycho diagnostic Assessment Strategies for Challenging Diagnostic Cases, South Florida Orthodox Mental Health Retreat. Sunny Isles Beach, FL March 13, 2005

Mental Status Exam, Presentation to First year Medical Students, Charles E Schmidt College of Medicine, January 24, 2013

Pediatric Autism Spectrum Disorder: An Overview, University Learning Systems, Eastern Caribbean Cruise, March 15, 2013

Pharmacogenomics in Everyday Psychiatric Practice, University Learning Systems, Panama Canal Cruise, March 15, 2017

rTMS in Clinical Practice, University Learning Systems, Bonita Springs, FL, January 24, 2018

Current Applications of TMS and Update on Autism, University at Sea, Western Caribbean Cruise, October 11, 2021

Update on ADHD and Pharmacogenomics, University at Sea, Western Caribbean Cruise, October 13, 2021

Mental Status Exam and Application of Pharmacogenomics to Everyday Clinical Practice, University at Sea, Alaska Cruise, June 13, 2023 and Italy and Croatia Cruise, October 20, 2024

TMS an Update, University at Sea, Alaska Cruise, June 17, 2023 and Italy and Croatia Cruise, October 20, 2024

Updates in the Treatment of ADHD, University at Sea, Alaska Cruise, June 17, 2023 and Italy and Croatia Cruise, October 26, 2024

Updates in the Treatment of Autism Spectrum Disorders, University at Sea, Alaska Cruise, June 18, 2023 and Italy and Croatia Cruise, October 26, 2024

Applications of Psychedelics for Psychiatric Use, University at Sea, Italy and Croatia Cruise, October 24, 2024

## **EMPLOYMENT**

Coral Shores Behavioral Health  
Stuart, FL  
Staff Physician  
December 2023-present

Certified Clinician for Major League Baseball Therapeutic Use Exemption Program  
November 2016- November 2019

Onward Living Recovery  
Boca Raton, FL  
Medical Director  
July 2019-present

Marriage and Family Services  
Delray Beach, FL and Planation, FL  
Medical Director  
March 2016-present

Seacrest Recovery Center  
Boynton Beach, FL  
Medical Director  
August 2015-July 2024

South Florida TMS, LLC  
Boca Raton and Miami, FL  
Medical Director  
July 2015-present

Chrysalis TMS Institute, Inc  
Boca Raton and Miami, FL  
Medical Director  
June 2013-July 2015

Gil Lichtshein, M.D., P.A.  
7100 West Camino Real, Suite 404  
Boca Raton, FL 33433  
Psychiatrist/President  
January 2009- present

Health Sciences America, Inc.  
1515 N. Federal Hwy; Suite 215  
Boca Raton, FL 33432  
Sub-Investigator  
Jan 2006 – July 2015

Boca Raton Psychiatric Group  
7284 W. Palmetto Park Road, Suite 201  
Boca Raton, FL 33433  
Psychiatrist/Partner  
August 2003-December 2008

Four Winds Hospital  
Katonah, NY 10536  
Medical Director, Cliffside Children's Inpatient Unit

Medical Director, Child and Adolescent Partial Hospitalization Program  
October 2000-August 2003

Private Practice  
Katonah, NY 10536  
February 2001-August 2003

St Christopher Otilie, Inc.  
Bronx Family Based Treatment Program  
Bronx, NY 10461  
Psychiatric Consultant  
August 1999-May 2001

Bronx Lebanon Hospital Center  
Department of Psychiatry  
Bronx, NY 10457  
Staff Psychiatrist  
July 1999-October 2000

### **PROFESSIONAL ORGANIZATIONS**

Fellow, American Psychiatric Association  
Fellow, American Academy of Child and Adolescent Psychiatry  
South Florida Regional Council  
Member, Fifteenth Judicial Circuit Grievance Committee "C", 4/07-3/10

### **PERSONAL**

HOBBIES: Reading, Sports, Civil War History, Travel, Exotic Foods